Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition

CD19-directed CAR T-cell therapy (CAR T) is effective in relapsed/refractory large B-cell lymphoma (R/R LBCL), but the role of bridging therapy (BT) remains incompletely defined. We analyzed 1,134 patients with R/R LBCL treated with axicabtagene ciloleucel or tisagenlecleucel between 2018 and July 2023. BT was categorized as polatuzumab vedotin-bendamustine-rituximab (Pola-BR), low-dose regimens, classical salvage chemo-immunotherapy, or radiotherapy. Overall survival (OS) and progression-free survival (PFS) from CAR T infusion were primary endpoints. Overall, 900 patients (79.5%) received BT and 232 (20.5%) did not (No-BT). At lymphodepletion, BT recipients more often had elevated LDH, bulky disease, and ECOG ≥2, yet had higher complete remission rates. Three-year PFS was 34.3% with BT versus 44.7% with No-BT, and OS was 44.4% versus 57.4%. In multivariable analyses, No-BT remained associated with superior OS (HR 0.63, 95% CI 0.49-0.82) and PFS (HR 0.69, 95% CI 0.55-0.87). Improvement in disease status between apheresis and lymphodepletion occurred more often with BT and was associated with improved outcomes (3-year PFS 47.5% vs. 28.9 and 27.7% for stable/worsened disease among BT recipients). BT modality influenced conversion rates but not adjusted OS, PFS, or relapse. Our data suggest bridging therapy may prioritize disease control with minimal toxicity rather than any specific regimen.

Authors

Institutions

Publication Details

Journal
Bone Marrow Transplantation
Published
2026-11-13
DOI
https://doi.org/10.1038/s41409-026-03074-x
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition

Norbert Schmitz, Barbara Dreta, Avichai Shimoni, Wolfgang Andreas Bethge et al.
3 links
Bone Marrow Transplantation
CAR-T cell therapy research
article

Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition

Norbert Schmitz, Barbara Dreta, Avichai Shimoni, Wolfgang Andreas Bethge, Imke E. Karsten, Ali A. Bazarbachi, Almudena Cabero, David Beauvais, Georg Lenz, Philipp Berning, Ulf Schnetzke, Michael Oertel, Christophe Peczynski, Ron Ram, Jan C. Schroeder, Robin Noël, Daniela Taurino, Olaf Penack, Eugenio Galli, Urban Novak, Bjoern Chapuy, Anna Maria Sureda, Peter Vandenberghe, Robin Sanderson, Peter Dreger, Ralph Wäsch, Evgenii Shumilov, Anna Ossami Saidy, Maxime Delforge, Malte von Bonin, Eva Michel, Bertram Glaß, Fizza Imran, On behalf of the GoCART Coalition
article en

Abstract

CD19-directed CAR T-cell therapy (CAR T) is effective in relapsed/refractory large B-cell lymphoma (R/R LBCL), but the role of bridging therapy (BT) remains incompletely defined. We analyzed 1,134 patients with R/R LBCL treated with axicabtagene ciloleucel or tisagenlecleucel between 2018 and July 2023. BT was categorized as polatuzumab vedotin-bendamustine-rituximab (Pola-BR), low-dose regimens, classical salvage chemo-immunotherapy, or radiotherapy. Overall survival (OS) and progression-free survival (PFS) from CAR T infusion were primary endpoints. Overall, 900 patients (79.5%) received BT and 232 (20.5%) did not (No-BT). At lymphodepletion, BT recipients more often had elevated LDH, bulky disease, and ECOG ≥2, yet had higher complete remission rates. Three-year PFS was 34.3% with BT versus 44.7% with No-BT, and OS was 44.4% versus 57.4%. In multivariable analyses, No-BT remained associated with superior OS (HR 0.63, 95% CI 0.49-0.82) and PFS (HR 0.69, 95% CI 0.55-0.87). Improvement in disease status between apheresis and lymphodepletion occurred more often with BT and was associated with improved outcomes (3-year PFS 47.5% vs. 28.9 and 27.7% for stable/worsened disease among BT recipients). BT modality influenced conversion rates but not adjusted OS, PFS, or relapse. Our data suggest bridging therapy may prioritize disease control with minimal toxicity rather than any specific regimen.

Bone Marrow Transplantation
University of Bern (CH), University Hospital Centre Zagreb (HR), University of Freiburg (DE), Tel Aviv University (IL), Universidad de Salamanca (ES), Heidelberg University (DE), Tel Aviv Sourasky Medical Center (IL), Sheba Medical Center (IL), Universitair Ziekenhuis Leuven (BE), University Hospital of Bern (CH), Agostino Gemelli University Polyclinic (IT), Centre Hospitalier Universitaire de Lille (FR), Institut d'Investigació Biomédica de Bellvitge (ES), European Society for Blood and Marrow Transplantation (NL), University Hospital Münster (DE), American University of Beirut Medical Center (LB), Institut Català d'Oncologia (ES), Instituto de Investigación Biomédica de Salamanca (ES), Jena University Hospital (DE), Centro de Investigación del Cáncer (ES), King's College Hospital (GB), Helios Hospital Berlin-Buch (DE), Centro de Investigación Biomédica en Red de Cáncer (ES), European Society for Blood and Marrow Transplantation (FR), IRCCS Humanitas Research Hospital (IT), Instituto de Biología Molecular y Celular del Cáncer de Salamanca (ES), Universitat de Barcelona (ES), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), American University of Beirut (LB)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon